IDH1 and central nervous system cancer: Based on our risk score model, we found that glioma samples (both LGGs and GBM) with an IDH1-mutant type have lower risk scores than IDH1wild-type samples, and the risk scores in LGGs with IDH1-mutant and 1p/19q codeletion samples have lower risk scores compared with than IDH1-mutant and 1p/19q non-codeletion samples.